Company / Accounts Receivable
CHAMPIONS ONCOLOGY, INC. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$9.5M
FY2025
5-year range
$7.0M / $9.5M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$10M in FY2025 with a 5-year CAGR of +14.8%.
Remained stable around $10M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +10.9%
- 5-Year CAGR
- +14.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +14.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 0.0% year-over-year.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5M | +0.0% |
| FY2024 | $9.5M | +0.1% |
| FY2023 | $9.5M | +36.2% |
| FY2022 | $7.0M | +0.0% |
| FY2021 | $7.0M | +46.5% |
| FY2020 | $4.8M | +9.0% |
| FY2019 | $4.4M | +11.7% |
| FY2018 | $3.9M | +72.3% |
| FY2017 | $2.3M | +73.3% |
| FY2016 | $1.3M | +23.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026